Bode W, Toet A E, Stolker A A, van Ginkel L A, Groen K, Wemer J, de Wildt D J
Laboratory of Medicines and Medical Devices, National Institute of Public Health and Environmental Protection, Bilthoven, The Netherlands.
Chirality. 1995;7(8):626-31. doi: 10.1002/chir.530070813.
Conscious male Wistar SPF Riv:TOX rats were dosed intravenously with 2.5, 5, or 10 mg/kg rac-propranolol.HCl, or with 5 mg/kg of either (-)-(S)- or (+)-(R)-propranolol.HCl. Disposition of (-)-(S)- and (+)-(R)-propranolol after dosing of rac-propranolol was linear in the dose range examined. Total plasma clearance was not changed in animals dosed with the individual enantiomers compared to the animals that were dosed with rac-propranolol. However, for (-)-(S)-propranolol both volume of distribution and elimination half-life decreased, whereas for (+)-(R)-propranolol increases were observed for these characteristics, in animals dosed with the individual enantiomers. Our observations suggest that the (+)-(R)-enantiomer competes with (-)-(S)-propranolol for plasma protein binding sites, resulting in lower plasma protein binding of the (-)-(S)-enantiomer when the racemate is administered. From recent toxicological experiments, it was concluded that rac-propranolol is more toxic than the individual enantiomers in the rat, when dosed iv at the same total mass. It is concluded that the observed potentiation of toxic effects of propranolol enantiomers when administered as a racemate can at least partly be explained by a pharmacokinetic interaction.
将雄性Wistar SPF Riv:TOX大鼠清醒后,静脉注射2.5、5或10mg/kg消旋普萘洛尔盐酸盐,或5mg/kg的(-)-(S)-或(+)-(R)-普萘洛尔盐酸盐。在研究的剂量范围内,消旋普萘洛尔给药后(-)-(S)-和(+)-(R)-普萘洛尔的处置呈线性。与给予消旋普萘洛尔的动物相比,给予单一对映体的动物的总血浆清除率没有变化。然而,对于(-)-(S)-普萘洛尔,分布容积和消除半衰期均降低,而对于(+)-(R)-普萘洛尔,给予单一对映体的动物中这些特征则增加。我们的观察结果表明,(+)-(R)-对映体与(-)-(S)-普萘洛尔竞争血浆蛋白结合位点,导致给予外消旋体时(-)-(S)-对映体的血浆蛋白结合降低。从最近的毒理学实验得出结论,当以相同总质量静脉给药时,消旋普萘洛尔在大鼠中比单一对映体毒性更大。得出的结论是,当作为外消旋体给药时,观察到的普萘洛尔对映体毒性增强至少部分可以由药代动力学相互作用来解释。